Advances in monitoring anticoagulant therapy
- PMID: 31122609
- DOI: 10.1016/bs.acc.2019.01.005
Advances in monitoring anticoagulant therapy
Abstract
Anticoagulant drugs directly or indirectly influence coagulation factors preventing fibrin formation, thus preventing blood clotting. They are classified into two groups according to the mode of application, namely parenteral and oral drugs. Among the latter, vitamin K antagonists (most often warfarin) were most widely used for almost a century. In recent years new oral anticoagulant drugs have become available that directly target either factor IIa or Xa (direct oral anticoagulants, DOACs). The proportion of patients to whom DOACs are prescribed is increasing because clinical studies have proved they are at least as effective and safe as vitamin K antagonists. Some of the anticoagulant drugs require regular laboratory monitoring, while others only need assessment of blood drug levels in specific clinical situations. This chapter provides an overview of appropriate laboratory tests used for either regular laboratory monitoring of therapy or occasional assessment of the anticoagulant effect of both parenteral and oral anticoagulant drugs used in clinical practice.
Keywords: Anticoagulants; Laboratory methods; Rotational thrombelastometry; Screening coagulation assay.
© 2019 Elsevier Inc. All rights reserved.
Similar articles
-
Laboratory Monitoring or Measurement of Direct Oral Anticoagulants (DOACs): Advantages, Limitations and Future Challenges.Curr Drug Metab. 2017;18(7):598-608. doi: 10.2174/1389200218666170417124035. Curr Drug Metab. 2017. PMID: 28413976 Review.
-
Coagulation assays and anticoagulant monitoring.Hematology Am Soc Hematol Educ Program. 2012;2012:460-5. doi: 10.1182/asheducation-2012.1.460. Hematology Am Soc Hematol Educ Program. 2012. PMID: 23233620 Review.
-
An update on laboratory assessment for direct oral anticoagulants (DOACs).Int J Lab Hematol. 2019 May;41 Suppl 1:33-39. doi: 10.1111/ijlh.12992. Int J Lab Hematol. 2019. PMID: 31069969 Review.
-
A new era for oral anticoagulation? Old and new anticoagulant drugs.Acta Cardiol. 2007 Apr;62(2):189-98. doi: 10.2143/AC.62.2.2020241. Acta Cardiol. 2007. PMID: 17536609 Review.
-
Differential cellular effects of old and new oral anticoagulants: consequences to the genesis and progression of atherosclerosis.Thromb Haemost. 2014 Nov;112(5):909-17. doi: 10.1160/TH14-03-0268. Epub 2014 Oct 9. Thromb Haemost. 2014. PMID: 25298033 Review.
Cited by
-
Antithrombotic therapy in adults with ectatic coronary artery disease: a systematic review and network meta-analysis.Egypt Heart J. 2025 Jan 22;77(1):13. doi: 10.1186/s43044-025-00612-8. Egypt Heart J. 2025. PMID: 39841407 Free PMC article. Review.
-
Biological Variation in Rotational Thromboelastometry in Patients with Atrial Fibrillation Receiving Rivaroxaban.J Cardiovasc Dev Dis. 2022 Jun 29;9(7):205. doi: 10.3390/jcdd9070205. J Cardiovasc Dev Dis. 2022. PMID: 35877567 Free PMC article.
-
Coumarin's Anti-Quorum Sensing Activity Can Be Enhanced When Combined with Other Plant-Derived Small Molecules.Molecules. 2021 Jan 3;26(1):208. doi: 10.3390/molecules26010208. Molecules. 2021. PMID: 33401594 Free PMC article.
-
Coumarin-piperazine derivatives as biologically active compounds.Saudi Pharm J. 2020 Feb;28(2):220-232. doi: 10.1016/j.jsps.2019.11.025. Epub 2019 Dec 7. Saudi Pharm J. 2020. PMID: 32042262 Free PMC article. Review.
-
Screening of the Promising Direct Thrombin Inhibitors from Haematophagous Organisms. Part I: Recombinant Analogues and Their Antithrombotic Activity In Vitro.Biomedicines. 2021 Dec 22;10(1):11. doi: 10.3390/biomedicines10010011. Biomedicines. 2021. PMID: 35052692 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical